Junkan Zhu

Zhongshan, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Is phrenic nerve-sparing worthwhile for phrenic-involved thymic epithelial tumors? A retrospective cohort study.

Is phrenic nerve-sparing worthwhile for phrenic-involved thymic epithelial tumors? A retrospective cohort study.

Journal: JTCVS open
Published: January 30, 2026

Cytokines and cancer-associated fibroblasts.

Cytokines and cancer-associated fibroblasts.

Journal: Journal of hematology & oncology
Published: January 02, 2026

Multi-omics profiling reveals intrathymic triggers and novel biomarkers in thymoma-associated myasthenia gravis.

Multi-omics profiling reveals intrathymic triggers and novel biomarkers in thymoma-associated myasthenia gravis.

Journal: Biomarker research
Published: November 07, 2025

Unveiling DEFB1 as a novel driver and promising therapeutic target in lung adenocarcinoma.

Unveiling DEFB1 as a novel driver and promising therapeutic target in lung adenocarcinoma.

Journal: Cell death & disease
Published: August 25, 2025

Targeting inosine metabolism to enhance EGFR-targeted therapy in lung adenocarcinoma.

Targeting inosine metabolism to enhance EGFR-targeted therapy in lung adenocarcinoma.

Journal: Cancer letters
Published: August 01, 2025

Robot-assisted versus video-assisted thoracoscopic thymectomy for stage I-II thymic epithelial tumour: a protocol for the first multicentre, randomised controlled clinical trial.

Robot-assisted versus video-assisted thoracoscopic thymectomy for stage I-II thymic epithelial tumour: a protocol for the first multicentre, randomised controlled clinical trial.

Journal: BMJ open
Published: May 29, 2025

The heterogeneity of thoracic Castleman disease: implications for classification and personalized management.

The heterogeneity of thoracic Castleman disease: implications for classification and personalized management.

Journal: Annals of hematology
Published: March 02, 2025

ZNF146 accelerates lung adenocarcinoma progression through MDM2/p53 and PHGDH/ferroptosis.

ZNF146 accelerates lung adenocarcinoma progression through MDM2/p53 and PHGDH/ferroptosis.

Journal: Cell & bioscience
Published: February 24, 2025

Transcription factor ZNF266 suppresses cancer progression by modulating CA9-mediated intracellular pH alteration in lung adenocarcinoma.

Transcription factor ZNF266 suppresses cancer progression by modulating CA9-mediated intracellular pH alteration in lung adenocarcinoma.

Journal: Respiratory research
Published: January 11, 2025

Ferroptosis-induced SUMO2 lactylation counteracts ferroptosis by enhancing ACSL4 degradation in lung adenocarcinoma.

Ferroptosis-induced SUMO2 lactylation counteracts ferroptosis by enhancing ACSL4 degradation in lung adenocarcinoma.

Journal: Cell discovery
Published: December 31, 2024

Targeting ALDH16A1 mediated thioredoxin lysosomal degradation to enhance ferroptosis susceptibility in SMARCA4-deficient NSCLC.

Targeting ALDH16A1 mediated thioredoxin lysosomal degradation to enhance ferroptosis susceptibility in SMARCA4-deficient NSCLC.

Journal: Nature communications
Published: November 04, 2024

Nuclear epidermal growth factor receptor (nEGFR) in clinical treatment.

Nuclear epidermal growth factor receptor (nEGFR) in clinical treatment.

Journal: Heliyon
Published: June 11, 2024
Showing 1-12 of 13

Last Updated: 09/26/2026